keyword
https://read.qxmd.com/read/38616254/shared-genetic-architecture-between-autoimmune-disorders-and-b-cell-acute-lymphoblastic-leukemia-insights-from-large-scale-genome-wide-cross-trait-analysis
#1
JOURNAL ARTICLE
Xinghao Yu, Yiyin Chen, Jia Chen, Yi Fan, Huimin Lu, Depei Wu, Yang Xu
BACKGROUND: To study the shared genetic structure between autoimmune diseases and B-cell acute lymphoblastic leukemia (B-ALL) and identify the shared risk loci and genes and genetic mechanisms involved. METHODS: Based on large-scale genome-wide association study (GWAS) summary-level data sets, we observed genetic overlaps between autoimmune diseases and B-ALL, and cross-trait pleiotropic analysis was performed to detect shared pleiotropic loci and genes. A series of functional annotation and tissue-specific analysis were performed to determine the influence of pleiotropic genes...
April 15, 2024: BMC Medicine
https://read.qxmd.com/read/38610997/synergy-between-brd9-and-ikzf3-targeting-as-a-therapeutic-strategy-for-multiple-myeloma
#2
JOURNAL ARTICLE
Basudev Chowdhury, Swati Garg, Wei Ni, Martin Sattler, Dana Sanchez, Chengcheng Meng, Taisei Akatsu, Richard Stone, William Forrester, Edmund Harrington, Sara J Buhrlage, James D Griffin, Ellen Weisberg
Progress in the treatment of multiple myeloma (MM) has resulted in improvement in the survival rate. However, there is still a need for more efficacious and tolerated therapies. We and others have shown that bromodomain-containing protein 9 (BRD9), a member of the non-canonical SWI/SNF chromatin remodeling complex, plays a role in MM cell survival, and targeting BRD9 selectively blocks MM cell proliferation and synergizes with IMiDs. We found that synergy in vitro is associated with the downregulation of MYC and Ikaros proteins, including IKZF3, and overexpression of IKZF3 or MYC could partially reverse synergy...
March 28, 2024: Cancers
https://read.qxmd.com/read/38567749/vitamin-d-constrains-inflammation-by-modulating-the-expression-of-key-genes-on-chr17q12-21-1
#3
JOURNAL ARTICLE
Ayse Kilic, Arda Halu, Margherita De Marzio, Enrico Maiorino, Melody G Duvall, Thayse Brueggemann, Joselyn J Rojas Quintero, Robert Chase, Hooman Mirzakhani, Ayse Özge Sungur, Janine Koepke, Taiji Nakano, Hong Yong Peh, Nandini Krishnamoorthy, Raja-Elie Abdulnour, Katia Georgopoulos, Augusto A Litonjua, Marie Demay, Harald Renz, Bruce D Levy, Scott T Weiss
Vitamin D possesses immunomodulatory functions and vitamin D deficiency has been associated with the rise in chronic inflammatory diseases, including asthma (Litonjua and Weiss, 2007). Vitamin D supplementation studies do not provide insight into the molecular genetic mechanisms of vitamin D-mediated immunoregulation. Here, we provide evidence for vitamin D regulation of two human chromosomal loci, Chr17q12-21.1 and Chr17q21.2, reliably associated with autoimmune and chronic inflammatory diseases. We demonstrate increased vitamin D receptor ( Vdr ) expression in mouse lung CD4+ Th2 cells, differential expression of Chr17q12-21...
April 3, 2024: ELife
https://read.qxmd.com/read/38559242/orthogonal-imid-degron-pairs-induce-selective-protein-degradation-in-cells
#4
Patrick J Brennan, Rebecca E Saunders, Mary Spanou, Marta Serafini, Liang Sun, Guillaume P Heger, Agnieszka Konopacka, Ryan D Beveridge, Laurie Gordon, Shenaz B Bunally, Aurore Saudemont, Andrew B Benowitz, Carlos Martinez-Fleites, Markus A Queisser, Heeseon An, Charlotte M Deane, Michael M Hann, Lewis L Brayshaw, Stuart J Conway
UNLABELLED: Immunomodulatory imide drugs (IMiDs) including thalidomide, lenalidomide, and pomalidomide, can be used to induce degradation of a protein of interest that is fused to a short zinc finger (ZF) degron motif. These IMiDs, however, also induce degradation of endogenous neosubstrates, including IKZF1 and IKZF3. To improve degradation selectivity, we took a bump-and-hole approach to design and screen bumped IMiD analogs against 8380 ZF mutants. This yielded a bumped IMiD analog that induces efficient degradation of a mutant ZF degron, while not affecting other cellular proteins, including IKZF1 and IKZF3...
March 16, 2024: bioRxiv
https://read.qxmd.com/read/38539501/mezigdomide-a-novel-cereblon-e3-ligase-modulator-under-investigation-in-relapsed-refractory-multiple-myeloma
#5
REVIEW
Monique A Hartley-Brown, Clifton C Mo, Omar Nadeem, Shonali Midha, Jacob P Laubach, Paul G Richardson
Mezigomide is an oral cereblon E3 ligase modulator (CELMoD) that is under clinical investigation in patients with relapsed/refractory (RR) multiple myeloma (MM). Like other CELMoD compounds, mezigdomide acts by altering the conformation of cereblon within the cullin 4A ring ligase-cereblon (CRL4CRBN) E3 ubiquitin ligase complex, thereby recruiting novel protein substrates for selective proteasomal degradation. These include two critical lymphoid transcription factors, Ikaros family zinc finger proteins 1 and 3 (IKZF1 and IKZF3), also known as Ikaros and Aiolos, which have important roles in the development and differentiation of hematopoietic cells, in MM pathobiology, and in suppressing the expression of interferon-stimulating genes and T-cell stimulation...
March 15, 2024: Cancers
https://read.qxmd.com/read/38379051/multimodal-and-spatially-resolved-profiling-identifies-distinct-patterns-of-t-cell-infiltration-in-nodal-b-cell-lymphoma-entities
#6
JOURNAL ARTICLE
Tobias Roider, Marc A Baertsch, Donnacha Fitzgerald, Harald Vöhringer, Berit J Brinkmann, Felix Czernilofsky, Mareike Knoll, Laura Llaó-Cid, Anna Mathioudaki, Bianca Faßbender, Maxime Herbon, Tobias Lautwein, Peter-Martin Bruch, Nora Liebers, Christian M Schürch, Verena Passerini, Marc Seifert, Alexander Brobeil, Gunhild Mechtersheimer, Carsten Müller-Tidow, Oliver Weigert, Martina Seiffert, Garry P Nolan, Wolfgang Huber, Sascha Dietrich
The redirection of T cells has emerged as an attractive therapeutic principle in B cell non-Hodgkin lymphoma (B-NHL). However, a detailed characterization of lymphoma-infiltrating T cells across B-NHL entities is missing. Here we present an in-depth T cell reference map of nodal B-NHL, based on cellular indexing of transcriptomes and epitopes, T cell receptor sequencing, flow cytometry and multiplexed immunofluorescence applied to 101 lymph nodes from patients with diffuse large B cell, mantle cell, follicular or marginal zone lymphoma, and from healthy controls...
February 20, 2024: Nature Cell Biology
https://read.qxmd.com/read/38314276/expression-levels-of-gsdmb-and-ormdl3-are-associated-with-relapsing-remitting-multiple-sclerosis-and-ikzf3-rs12946510-variant
#7
JOURNAL ARTICLE
Milan Stefanović, Ljiljana Stojković, Ivan Životić, Evica Dinčić, Aleksandra Stanković, Maja Živković
Multiple sclerosis (MS), a noncurable autoimmune neurodegenerative disease, requires constant research that could improve understanding of both environmental and genetic factors that lead to its occurrence and/or progression. Recognition of the genetic basis of MS further leads to an investigation of the regulatory role of genetic variants on gene expression. Among risk variants for MS, Ikaros zinc finger 3 ( IKZF3) gene variant rs12946510 was identified as one of the top-ranked and the expression quantitative trait loci (eQTL) for genes residing in chromosomal locus 17q12-21...
February 15, 2024: Heliyon
https://read.qxmd.com/read/38300987/discovery-and-preclinical-pharmacology-of-nx-2127-an-orally-bioavailable-degrader-of-bruton-s-tyrosine-kinase-with-immunomodulatory-activity-for-the-treatment-of-patients-with-b-cell-malignancies
#8
JOURNAL ARTICLE
Daniel W Robbins, Mark A Noviski, Ying Siow Tan, Zef A Konst, Aileen Kelly, Paul Auger, Nivetha Brathaban, Robert Cass, Ming Liang Chan, Ganesh Cherala, Matthew C Clifton, Stefan Gajewski, Timothy G Ingallinera, Dane Karr, Daisuke Kato, Jun Ma, Jenny McKinnell, Joel McIntosh, Jeff Mihalic, Brent Murphy, Jaipal Reddy Panga, Ge Peng, Janine Powers, Luz Perez, Ryan Rountree, Austin Tenn-McClellan, Arthur T Sands, Dahlia R Weiss, Jeffrey Wu, Jordan Ye, Cristiana Guiducci, Gwenn Hansen, Frederick Cohen
Bruton's tyrosine kinase (BTK), a member of the TEC family of kinases, is an essential effector of B-cell receptor (BCR) signaling. Chronic activation of BTK-mediated BCR signaling is a hallmark of many hematological malignancies, which makes it an attractive therapeutic target. Pharmacological inhibition of BTK enzymatic function is now a well-proven strategy for the treatment of patients with these malignancies. We report the discovery and characterization of NX-2127, a BTK degrader with concomitant immunomodulatory activity...
February 1, 2024: Journal of Medicinal Chemistry
https://read.qxmd.com/read/38228616/selective-ck1%C3%AE-degraders-exert-antiproliferative-activity-against-a-broad-range-of-human-cancer-cell-lines
#9
JOURNAL ARTICLE
Gisele Nishiguchi, Lauren G Mascibroda, Sarah M Young, Elizabeth A Caine, Sherif Abdelhamed, Jeffrey J Kooijman, Darcie J Miller, Sourav Das, Kevin McGowan, Anand Mayasundari, Zhe Shi, Juan M Barajas, Ryan Hiltenbrand, Anup Aggarwal, Yunchao Chang, Vibhor Mishra, Shilpa Narina, Melvin Thomas, Allister J Loughran, Ravi Kalathur, Kaiwen Yu, Suiping Zhou, Xusheng Wang, Anthony A High, Junmin Peng, Shondra M Pruett-Miller, Danette L Daniels, Marjeta Urh, Anang A Shelat, Charles G Mullighan, Kristin M Riching, Guido J R Zaman, Marcus Fischer, Jeffery M Klco, Zoran Rankovic
Molecular-glue degraders are small molecules that induce a specific interaction between an E3 ligase and a target protein, resulting in the target proteolysis. The discovery of molecular glue degraders currently relies mostly on screening approaches. Here, we describe screening of a library of cereblon (CRBN) ligands against a panel of patient-derived cancer cell lines, leading to the discovery of SJ7095, a potent degrader of CK1α, IKZF1 and IKZF3 proteins. Through a structure-informed exploration of structure activity relationship (SAR) around this small molecule we develop SJ3149, a selective and potent degrader of CK1α protein in vitro and in vivo...
January 16, 2024: Nature Communications
https://read.qxmd.com/read/38216003/ikzf3-aiolos-h195y-mutation-identified-in-a-mouse-model-of-b-cell-leukemia-results-in-altered-dna-binding-and-altered-stat5-dependent-gene-expression
#10
JOURNAL ARTICLE
Bruno Rodrigues de Oliveira, James Iansavitchous, Heidi Rysan, Wei Cen Wang, Mia P Sams, Devon Knight, Li S Xu, Jeewoo Jeong, Thomas P Qu, Alexandra P Zorzi, Rodney P DeKoter
Precursor B cell acute lymphoblastic leukemia (Pre-B-ALL) arises from developing B cells and frequently involves mutations in genes encoding transcription factors. In this study, we investigated the function of mutations in the transcription factor IKZF3 (Aiolos), R137* and H195Y, discovered in a mouse model of pre-B-ALL. R137* IKZF3 mutation resulted in a truncated protein, while electrophoretic mobility shift assay showed that H195Y IKZF3 mutation resulted in a protein with altered DNA binding. 38B9 pre-B cell lines were generated expressing WT and H195Y IKZF3 proteins...
January 10, 2024: Gene
https://read.qxmd.com/read/38193570/genetic-variations-in-ikzf3-let7-a2-and-cdkn2b-as1-exploring-associations-with-metabolic-syndrome-susceptibility-and-clinical-manifestations
#11
JOURNAL ARTICLE
Alireza Paniri, Mohammad Mahdi Hosseini, Sadegh Fattahi, Galia Amiribozorgi, Mohsen Asouri, Mansooreh Maadi, Nima Motamed, Farhad Zamani, Haleh Akhavan-Niaki
BACKGROUND AND AIM: Metabolic syndrome (MetS) increases the risk of atherosclerosis and diabetes, but there are no approved predictive markers. This study assessed the role of specific genetic variations in MetS susceptibility and their impact on clinical manifestations. METHOD: In this study, a genotype-phenotype assessment was performed for IKZF3 (rs907091), microRNA-let-7a-2 (rs1143770), and lncRNA-CDKN2B-AS1 (rs1333045). RESULTS: Analyses indicate that while rs907091 and rs1143770 may have potential associations with MetS susceptibility and an increased risk of atherosclerosis and diabetes, there is an observed trend suggesting that the rs1333045 CC genotype may be associated with a decreased risk of MetS...
January 9, 2024: Journal of Clinical Laboratory Analysis
https://read.qxmd.com/read/38182668/ikaros-and-aiolos-directly-regulate-ap-1-transcriptional-complexes-and-are-essential-for-nk-cell-development
#12
JOURNAL ARTICLE
Wilford Goh, Harrison Sudholz, Momeneh Foroutan, Sebastian Scheer, Aline Pfefferle, Rebecca B Delconte, Xiangpeng Meng, Zihan Shen, Robert Hennessey, Isabella Y Kong, Iona S Schuster, Christopher E Andoniou, Melissa J Davis, Soroor Hediyeh-Zadeh, Fernando Souza-Fonseca-Guimaraes, Ian A Parish, Paul Beavis, Daniel Thiele, Michael Chopin, Mariapia A Degli-Esposti, Joe Cursons, Axel Kallies, Jai Rautela, Stephen L Nutt, Nicholas D Huntington
Ikaros transcription factors are essential for adaptive lymphocyte function, yet their role in innate lymphopoiesis is unknown. Using conditional genetic inactivation, we show that Ikzf1/Ikaros is essential for normal natural killer (NK) cell lymphopoiesis and IKZF1 directly represses Cish, a negative regulator of interleukin-15 receptor resulting in impaired interleukin-15 receptor signaling. Both Bcl2l11 and BIM levels, and intrinsic apoptosis were increased in Ikzf1-null NK cells, which in part accounts for NK lymphopenia as both were restored to normal levels when Ikzf1 and Bcl2l11 were co-deleted...
February 2024: Nature Immunology
https://read.qxmd.com/read/38165043/induced-protein-degradation-for-therapeutics-past-present-and-future
#13
REVIEW
Hojong Yoon, Justine C Rutter, Yen-Der Li, Benjamin L Ebert
The concept of induced protein degradation by small molecules has emerged as a promising therapeutic strategy that is particularly effective in targeting proteins previously considered "undruggable." Thalidomide analogs, employed in the treatment of multiple myeloma, stand as prime examples. These compounds serve as molecular glues, redirecting the CRBN E3 ubiquitin ligase to degrade myeloma-dependency factors, IKZF1 and IKZF3. The clinical success of thalidomide analogs demonstrates the therapeutic potential of induced protein degradation...
January 2, 2024: Journal of Clinical Investigation
https://read.qxmd.com/read/38139431/dna-copy-number-alterations-and-copy-neutral-loss-of-heterozygosity-in-adult-ph-negative-acute-b-lymphoblastic-leukemia-focus-on-the-genes-involved
#14
JOURNAL ARTICLE
Natalya Risinskaya, Maria Gladysheva, Abdulpatakh Abdulpatakhov, Yulia Chabaeva, Valeriya Surimova, Olga Aleshina, Anna Yushkova, Olga Dubova, Nikolay Kapranov, Irina Galtseva, Sergey Kulikov, Tatiana Obukhova, Andrey Sudarikov, Elena Parovichnikova
The landscape of chromosomal aberrations in the tumor cells of the patients with B-ALL is diverse and can influence the outcome of the disease. Molecular karyotyping at the onset of the disease using chromosomal microarray (CMA) is advisable to identify additional molecular factors associated with the prognosis of the disease. Molecular karyotyping data for 36 patients with Ph-negative B-ALL who received therapy according to the ALL-2016 protocol are presented. We analyzed copy number alterations and their prognostic significance for CDKN2A / B , DMRTA , DOCK8 , TP53 , SMARCA2 , PAX5 , XPA , FOXE1 , HEMGN , USP45 , RUNX1 , NF1 , IGF2BP1 , ERG , TMPRSS2 , CRLF2 , FGFR3 , FLNB , IKZF1 , RUNX2 , ARID1B , CIP2A , PIK3CA , ATM , RB1 , BIRC3 , MYC , IKZF3 , ETV6 , ZNF384 , PTPRJ , CCL20 , PAX3 , MTCH2 , TCF3 , IKZF2 , BTG1 , BTG2 , RAG1 , RAG2 , ELK3 , SH2B3 , EP300 , MAP2K2 , EBI3 , MEF2D , MEF2C , CEBPA , and TBLXR1 genes, choosing t(4;11) and t(7;14) as reference events...
December 18, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/38049581/the-transcription-factor-aiolos-restrains-the-activation-of-intestinal-intraepithelial-lymphocytes
#15
JOURNAL ARTICLE
Kentaro Yomogida, Tihana Trsan, Raki Sudan, Patrick F Rodrigues, Alina Ulezko Antonova, Harshad Ingle, Blanda Di Luccia, Patrick L Collins, Marina Cella, Susan Gilfillan, Megan T Baldridge, Eugene M Oltz, Marco Colonna
Intestinal intraepithelial lymphocytes (IELs) exhibit prompt innate-like responses to microenvironmental cues and require strict control of effector functions. Here we showed that Aiolos, an Ikaros zinc-finger family member encoded by Ikzf3, acted as a regulator of IEL activation. Ikzf3-/- CD8αα+ IELs had elevated expression of NK receptors, cytotoxic enzymes, cytokines and chemokines. Single-cell RNA sequencing of Ikzf3-/- and Ikzf3+/+ IELs showed an amplified effector machinery in Ikzf3-/- CD8αα+ IELs compared to Ikzf3+/+ counterparts...
January 2024: Nature Immunology
https://read.qxmd.com/read/38018448/ikzf3-polymorphisms-contribute-to-the-increased-risk-of-acute-lymphoblastic-leukemia-in-children
#16
JOURNAL ARTICLE
Xu Yang, Lihua Yang, Annie Luo, Shanshan Liu, Xiaohong Zhang, Xiaoping Liu, Xiaodan Liu, Ailing Luo, Mansi Cai, Yaping Yan, Xuedong Wu, Ke Huang, Ling Xu, Hua Jiang
BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common cancer in children. IKZF3 (IKAROS family zinc finger 3) is a hematopoietic-specific transcription factor, and it has been validated that it is involved in leukemia. However, the role of IKZF3 single-nucleotide polymorphisms (SNPs) remains unclear. In this case-control study, the authors investigated the association of IKZF3 SNPs with ALL in children. METHODS: Six IKZF3 reference SNPs (rs9635726, rs2060941, rs907092, rs12946510, rs1453559, and rs62066988) were genotyped in 692 patients who had ALL (cases) and in 926 controls...
November 29, 2023: Cancer
https://read.qxmd.com/read/38015619/disease-associated-aiolos-variants-lead-to-immune-deficiency-dysregulation-by-haploinsufficiency-and-redefine-aiolos-functional-domains
#17
JOURNAL ARTICLE
Hye Sun Kuehn, Inga S Sakovich, Julie E Niemela, Agustin A Gil Silva, Jennifer L Stoddard, Ekaterina A Polyakova, Ana Esteve-Sole, Svetlana N Aleshkevich, Tatjana A Uglova, Mikhail V Belevtsev, Vladislav R Vertelko, Tatsiana V Shman, Aleksandra N Kupchinskaya, Jolan E Walter, Thomas A Fleisher, Luigi D Notarangelo, Xiao P Peng, Ottavia Maria Delmonte, Svetlana O Sharapova, Sergio D Rosenzweig
AIOLOS, also known as IKZF3, is a transcription factor highly expressed in the lymphoid lineage and critical for lymphocyte differentiation and development. Here we report nine individuals from three unrelated families carrying AIOLOS variants Q402* or E82K leading to AIOLOS haploinsufficiency through different mechanisms of action. Nonsense mutant Q402* displayed abnormal DNA binding, pericentromeric targeting, post-transcriptional modification, and transcriptome regulation. Structurally, the mutant lacks the AIOLOS zinc finger (ZF) 5-6 dimerization domain, but is still able to homodimerize with WT AIOLOS and negatively regulate DNA binding through ZF1, a previously unrecognized function for this domain...
November 28, 2023: Journal of Clinical Investigation
https://read.qxmd.com/read/37945755/genomic-and-immune-signatures-predict-clinical-outcome-in-newly-diagnosed-multiple-myeloma-treated-with-immunotherapy-regimens
#18
JOURNAL ARTICLE
Francesco Maura, Eileen M Boyle, David Coffey, Kylee Maclachlan, Dylan Gagler, Benjamin Diamond, Hussein Ghamlouch, Patrick Blaney, Bachisio Ziccheddu, Anthony Cirrincione, Monika Chojnacka, Yubao Wang, Ariel Siegel, James E Hoffman, Dickran Kazandjian, Hani Hassoun, Emily Guzman, Sham Mailankody, Urvi A Shah, Carlyn Tan, Malin Hultcrantz, Michael Scordo, Gunjan L Shah, Heather Landau, David J Chung, Sergio Giralt, Yanming Zhang, Arnaldo Arbini, Qi Gao, Mikhail Roshal, Ahmet Dogan, Alexander M Lesokhin, Faith E Davies, Saad Z Usmani, Neha Korde, Gareth J Morgan, Ola Landgren
Despite improving outcomes, 40% of patients with newly diagnosed multiple myeloma treated with regimens containing daratumumab, a CD38-targeted monoclonal antibody, progress prematurely. By integrating tumor whole-genome and microenvironment single-cell RNA sequencing from upfront phase 2 trials using carfilzomib, lenalidomide and dexamethasone with daratumumab ( NCT03290950 ), we show how distinct genomic drivers including high APOBEC mutational activity, IKZF3 and RPL5 deletions and 8q gain affect clinical outcomes...
December 2023: Nature Cancer
https://read.qxmd.com/read/37934799/etv4-dependent-transcriptional-plasticity-maintains-myc-expression-and-results-in-imid-resistance-in-multiple-myeloma
#19
JOURNAL ARTICLE
Paola Neri, Benjamin G Barwick, David Jung, Jonathan C Patton, Ranjan Maity, Ines Tagoug, Caleb K Stein, Remi Tilmont, Noemie Leblay, Sungwoo Ahn, Holly Lee, Seth J Welsh, Daniel L Riggs, Nicholas Stong, Erin Flynt, Anjan Thakurta, Jonathan J Keats, Sagar Lonial, P Leif Bergsagel, Lawrence H Boise, Nizar J Bahlis
Immunomodulatory Drugs (IMiDs) are a backbone therapy for multiple myeloma (MM). Despite their efficacy, most patients develop resistance, and the mechanism(s) are not fully defined. Here, we show that IMiD responses are directed by IMiD-dependent degradation of IKZF1 and IKZF3 that bind to enhancers necessary to sustain the expression of MYC and other myeloma oncogenes. IMiD treatment universally depleted chromatin-bound IKZF1, but eviction of P300 and BRD4 co-activators only occurred in IMiD-sensitive cells...
November 7, 2023: Blood cancer discovery
https://read.qxmd.com/read/37922905/single-cell-epigenetic-transcriptional-and-protein-profiling-of-latent-and-active-hiv-1-reservoir-revealed-that-ikzf3-promotes-hiv-1-persistence
#20
JOURNAL ARTICLE
Yulong Wei, Timothy C Davenport, Jack A Collora, Haocong Katherine Ma, Delia Pinto-Santini, Javier Lama, Ricardo Alfaro, Ann Duerr, Ya-Chi Ho
Understanding how HIV-1-infected cells proliferate and persist is key to HIV-1 eradication, but the heterogeneity and rarity of HIV-1-infected cells hamper mechanistic interrogations. Here, we used single-cell DOGMA-seq to simultaneously capture transcription factor accessibility, transcriptome, surface proteins, HIV-1 DNA, and HIV-1 RNA in memory CD4+ T cells from six people living with HIV-1 during viremia and after suppressive antiretroviral therapy. We identified increased transcription factor accessibility in latent HIV-1-infected cells (RORC) and transcriptionally active HIV-1-infected cells (interferon regulatory transcription factor [IRF] and activator protein 1 [AP-1])...
October 26, 2023: Immunity
keyword
keyword
40597
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.